Alzheimer’s Blood Tests and Risk Estimates Need Clinical Context
FDA-cleared blood tests remain intended to support assessment of symptomatic patients, not population screening. New reporting describes p-tau217 accuracy of at least 90% against established tests across three cohorts, and C2N and LSI Medience are pursuing Japanese approval for PrecivityAD2; neither development shows that screening improves outcomes. The proposed ASAP Act and Mayo risk estimates raise access and policy questions but do not justify asymptomatic testing.
Sources (13)
Updated Nov 21, 2026